ROCHE, Confidence building up on next gen. Rituxan (GA101)

Date: 2015-07

Roche seems to be on track of delivering sustainable growth as it announced today that Obinutuzumab (GA-101), follow-on biologic to Rituxan has demonstrated significant improvement of PFS against chemotherapy in first-line CLL in the first PhIII study. The DSMB has given a green signal to continue the study as futility analysis comparing GA-101 plus chlorambucil against Rituxan plus chlorambucil indicates potential superiority of GA-101 over Rituxan. Superiority claim over Rituxan will allow the company to protect its revenue from any biosimilar threat going forward. With Perjeta and T-DM1 as well shaping up well, Roche is on a strong ground to sustain its revenues from Herceptin and Rituxan (~12 billion). Biosimilar Rituxan is expected to reach the market in 2016, but by then, Roche would have GA101 on the market which would fend off any potential impact on revenues.

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample